Takeda Pharmaceutical (TAK) Cash from Financing Activities (2018 - 2026)

Takeda Pharmaceutical's Cash from Financing Activities history runs 9 years deep, the most recent figure standing at -$494.1 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 75.02% year-over-year to -$494.1 million in Q1 2026; TTM through Mar 2026 was -$3.3 billion, a 33.75% increase from a year earlier, with the FY2026 full-year figure at -$3.3 billion, up 33.09% from the prior year.
• Cash from Financing Activities climbed to -$494.1 million in Q1 2026 per TAK's latest filing, from -$1.3 billion in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $2.0 billion in Q2 2024 and bottomed at -$4.3 billion in Q4 2024.
• The 5-year median for Cash from Financing Activities is -$737.8 million (2024), against an average of -$1.1 billion.
• Biggest YoY gain for Cash from Financing Activities was 582.07% in 2024; the steepest drop was 687.4% in 2024.
• Year by year, Cash from Financing Activities stood at -$3.1 billion in 2022, then surged by 78.52% to -$661.4 million in 2023, then tumbled by 552.41% to -$4.3 billion in 2024, then surged by 71.02% to -$1.3 billion in 2025, then surged by 60.49% to -$494.1 million in 2026.
• Per Business Quant, the three latest TAK Cash from Financing Activities figures stand at -$494.1 million (Q1 2026), -$1.3 billion (Q4 2025), and -$81.3 million (Q3 2025).